Paper6135933
Desferrioxamine suppositories.
Kontoghiorghes G and 2 others. Lancet, 1983. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Desferrioxamine suppositories. Papers, record 6135933. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6135933
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Deferoxamine | Major topic |
| Humans | |
| Iron | |
| Suppositories |
Source PubMed
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42797332 | Insights into the Complexities of Pharmacotherapy Parameters in Artificial Intelligence Models for Drug Selection, Precision Personalised Medicine and Optimal Therapeutic Outcomes. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42797332 | PubMed |
| 40867878 | New Approaches and Strategies for the Repurposing of Iron Chelating/Antioxidant Drugs for Diseases of Free Radical Pathology in Medicine. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/40867878 | PubMed |
| 38562512 | Role of ferroptosis in Porphyromonas gingivalis-induced impairment of epithelial junction. | J Oral Microbiol | 2024 | https://conductscience.org/library/papers/38562512 | PubMed |
| 38069073 | Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38069073 | PubMed |
| 36902402 | Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36902402 | PubMed |
| 36430469 | New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36430469 | PubMed |
| 31934321 | The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia. | Mediterr J Hematol Infect Dis | 2020 | https://conductscience.org/library/papers/31934321 | PubMed |
| 28008230 | Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. | Drug Des Devel Ther | 2016 | https://conductscience.org/library/papers/28008230 | PubMed |
| 12825969 | Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. | Drug Saf | 2003 | https://conductscience.org/library/papers/12825969 | PubMed |
| 8262586 | Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. | Indian J Pediatr | 1993 | https://conductscience.org/library/papers/8262586 | PubMed |
| 3122880 | Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. | Br Med J (Clin Res Ed) | 1987 | https://conductscience.org/library/papers/3122880 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6135933
GET https://conductscience.org/api/papers/v1/6135933/authors